Arslan Liaqat/LinkedIn
Aug 8, 2026, 06:51
Arslan Liaqat: New Data on Iron Chelation in Thalassemia
Arslan Liaqat, Doctor of Medicine at BBH Rawalpindi, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in LMJHCR, adding:
“Excited to share the executive summary of our RCT on Deferasirox vs. Deferoxamine in Transfusion-Dependent Thalassemia (published in LMJHCR)!”
Title: Evaluating Effectiveness of Deferasirox Versus Deferoxamine in Improving Clinical Outcomes among Patients with Transfusion-Dependent Thalassemia: A Randomized Controlled Trial
Authors: Muhammad Mohsin Shoukat, Hafiza Khadija Tariq, Fareed Ullah, Muhammad Arslan Liaqat, Areeba Sajjad, Nauman Akhtar
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 09:51Ceasovschih Alexandr: A Closer Look at Lipid Disorders in CKM Syndrome
-
Sep 20, 2026, 09:05World Stroke Academy: Can Adjunct IAT Improve Tissue Reperfusion?
-
Sep 20, 2026, 06:46Neeraj Songara: From Donated Blood to Engineered Therapeutics
-
Sep 20, 2026, 06:24Louise St. Germain Bannon: Improving Awareness and Care for Women Across the Lifespan
-
Sep 20, 2026, 05:17Maxime Dely: When ABO Compatibility Isn’t Enough for Safe Transfusion
-
Sep 20, 2026, 04:54William Aird: What Does a Complete History and Physical Really Mean?
-
Sep 20, 2026, 04:34Hons Saurabh Kaushik: Why Uncontrolled LDL Can Be Harmful
-
Sep 20, 2026, 03:58Salih Ehsan: The Complexities of HbF and HbA2
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC